Karin Boslooper

Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study

André Wieringa, Karin Boslooper, Mels Hoogendoorn et al. · British Journal of Haematology · 2014 · 80 citations

Medicine, Hematology, Oncology +10

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome

Karin Boslooper, Robby E. Kibbelaar, Huib Storm et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 52 citations

Medicine, Geriatric Medicine, Oncology +17

The clinicopathological roles of alpha-B-crystallin and p53 expression in patients with head and neck squamous cell carcinoma

Karin Boslooper, Alfred K. Lam, Jin Gao et al. · Pathology · 2008 · 28 citations · Full text

Medicine, Molecular Biology, Oncology +14

No outcome disparities in patients with diffuse large B-cell lymphoma and a low socioeconomic status

Karin Boslooper, Mels Hoogendoorn, Eric N. van Roon et al. · Cancer Epidemiology · 2017 · 17 citations · Full text

Medicine, Hematology, Oncology +17

Relapse in stage I(E) diffuse large B‐cell lymphoma

Marcel Nijland, Karin Boslooper, Gustaaf van Imhoff et al. · Hematological Oncology · 2017 · 15 citations · Full text

Medicine, Hematology, Oncology +15